These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A social media microinfluencer intervention to reduce coronavirus disease 2019 vaccine hesitancy in underserved Tennessee communities: A protocol paper. Hohmeier KC; Barenie RE; Hagemann TM; Renfro C; Xing K; Phillips A; Allen R; Fiscus MD; Chisholm-Burns M; Gatwood J J Am Pharm Assoc (2003); 2022; 62(1):326-334. PubMed ID: 34893443 [TBL] [Abstract][Full Text] [Related]
5. Quantitative and qualitative assessment of an all-inclusive postpartum human papillomavirus vaccination program. Berenson AB; Hirth JM; Kuo YF; Rupp RE Am J Obstet Gynecol; 2021 May; 224(5):504.e1-504.e9. PubMed ID: 33248134 [TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
7. The Effect of a Student-Run Free Clinic on Hospital Utilization. Trumbo SP; Schuering KM; Kallos JA; Baddour N; Rakhit S; Wang L; Fowler M; Vasilevskis EE; Miller RF J Health Care Poor Underserved; 2018; 29(2):701-710. PubMed ID: 29805135 [TBL] [Abstract][Full Text] [Related]
8. Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January-March 2021. Sadigh KS; Kugeler KJ; Bressler S; Massay SC; Schmoll E; Milroy L; Cavanaugh AM; Sierocki A; ; Fischer M; Nolen LD BMC Infect Dis; 2022 Sep; 22(1):718. PubMed ID: 36050630 [TBL] [Abstract][Full Text] [Related]
9. Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation. Yousaf AR; Cortese MM; Taylor AW; Broder KR; Oster ME; Wong JM; Guh AY; McCormick DW; Kamidani S; Schlaudecker EP; Edwards KM; Creech CB; Staat MA; Belay ED; Marquez P; Su JR; Salzman MB; Thompson D; Campbell AP; Lancet Child Adolesc Health; 2022 May; 6(5):303-312. PubMed ID: 35216660 [TBL] [Abstract][Full Text] [Related]
10. [Technical guidelines for seasonal influenza vaccination in China (2021-2022)]. National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) , Influenza Vaccination TWG Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Oct; 42(10):1722-1749. PubMed ID: 34814607 [TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study. Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141 [TBL] [Abstract][Full Text] [Related]
12. Finally, an FDA Approval for an Immunization Against COVID-19: Hope on the Horizon. Powell J; Piszczatoski CR Ann Pharmacother; 2022 Sep; 56(9):1058-1064. PubMed ID: 35012364 [TBL] [Abstract][Full Text] [Related]
13. The pharmaceutical management system at Shade Tree Family Clinic: a medical student-run free clinic's experience. Rosenbaum BP; Patel SG; Guyer DL; Dunn SR; Herceg ME; Knox CK; Miller RF Inform Health Soc Care; 2008 Sep; 33(3):151-7. PubMed ID: 18850398 [TBL] [Abstract][Full Text] [Related]
14. Meharry Medical College Mobile Vaccination Program: Implications for Increasing COVID-19 Vaccine Uptake among Minority Communities in Middle Tennessee. Alcendor DJ; Juarez PD; Matthews-Juarez P; Simon S; Nash C; Lewis K; Smoot D Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214670 [TBL] [Abstract][Full Text] [Related]
15. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review. Külper-Schiek W; Piechotta V; Pilic A; Batke M; Dreveton LS; Geurts B; Koch J; Köppe S; Treskova M; Vygen-Bonnet S; Waize M; Wichmann O; Harder T Front Immunol; 2022; 13():940562. PubMed ID: 36091023 [TBL] [Abstract][Full Text] [Related]
16. Behavioral and social science in support of SARS-CoV-2 vaccination: National Institutes of Health initiatives. Hunter CM; Chou WS; Webb Hooper M Transl Behav Med; 2021 Jul; 11(7):1354-1358. PubMed ID: 34080616 [TBL] [Abstract][Full Text] [Related]
17. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19]. Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968 [TBL] [Abstract][Full Text] [Related]
18. Impact of the SARS-CoV-2 pandemic on vaccine-preventable disease campaigns. Ho LL; Gurung S; Mirza I; Nicolas HD; Steulet C; Burman AL; Danovaro-Holliday MC; Sodha SV; Kretsinger K Int J Infect Dis; 2022 Jun; 119():201-209. PubMed ID: 35398300 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]. Poh XY; Lee IR; Lim C; Teo J; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Ng LFP; Ren EC; Lin RTP; Wang LF; Renia L; Lye DC; Young BE Trials; 2022 Jun; 23(1):498. PubMed ID: 35710572 [TBL] [Abstract][Full Text] [Related]